Treatment failure patterns are similar between p16− and p16+ oropharyngeal squamous cell carcinomas. Issue 4 (1st June 2022)

• Record Type: Journal Article
• Authors: Hamill, Chelsea S.; Muller, Richard Grant; Clancy, Kate; Vu, Brandon; Gui, Shanying; Thuener, Jason Eric; Wasman, Jay; Li, Shawn; Fowler, Nicole; Rezaee, Rod; Lavertu, Pierre; Teknos, Theodoros N.; Pan, Quintin; O'Neill, Wendi Quinn
• Is Part Of: Laryngoscope investigative otolaryngology. Volume 7:Issue 4(2022)
• Page Start: 988
• Page End: 993
• Publication Date: 2022-06-01
• Subjects: disease progression -- head and neck cancer -- oropharyngeal cancer -- p16 -- treatment failure; Otolaryngology -- Periodicals; Laryngoscopy -- Periodicals; Otolaryngology; Otolaryngology; Periodicals; Periodicals; 617.51
• DOI: 10.1002/lio2.779
• Languages: English
• ISSNs: 2378-8038

Abstract

Abstract: Background: The incidence of p16+ oropharyngeal squamous cell carcinoma (OPSCC) has been increasing. The notion that p16+ OPSCC has a propensity for atypical and disseminating metastasis has gained traction. We compared treatment failure patterns in p16+ and p16− OPSCC and evaluated survival impact. Methods: Retrospective analysis of patients with recurrent/metastatic OPSCC disease between 1/2009 and 12/2019. Results: Thirty‐eight p16+ and 36 p16− patients were identified. Three distinct failure patterns (distant vs. locoregional, atypical vs. typical, and disseminating vs. non‐disseminating) were studied. No significant differences were found between p16+ and p16− patients. Multivariate analysis showed p16 status was an independent prognostic biomarker; p16+ patients have a favorable overall survival compared to p16− patients (HR 0.34, 95% CI 0.16–0.77; P = .005). Conclusions: We challenge the view that p16+ OPSCC exhibits a distinctive treatment failure pattern and showed that p16 status impacts patient survival independent of disease progression. Abstract : The incidence of p16+ oropharyngeal squamous cell carcinoma (OPSCC) has been increasing. The notion that p16+ OPSCC has a propensity for atypical and disseminating metastasis has gained traction. No significant differences were found between p16+ and p16− patients and three distinct failure patterns (distant vs. locoregional, atypical vs. typical, and disseminating vs. non‐disseminating). We challenge the view that p16+ OPSCC exhibits a distinctive treatment failure pattern and showed that p16 status impacts patient survival independent of disease progression.